Management of Relapsed and Refractory Hodgkin Lymphoma in 2018

被引：2
|
作者：
Rutherford, Sarah C. [1 ]
Leonard, John P. [1 ]
机构：
[1] Weill Cornell Med, New York Presbyterian Hosp, Weill Dept Med, Meyer Canc Ctr,Div Hematol & Med Oncol, 1305 York Ave,7th Floor, New York, NY 10021 USA
来源：
JAMA ONCOLOGY | 2018年 / 4卷 / 08期
关键词：
STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; NIVOLUMAB; TRIAL; MULTICOHORT; THERAPY; FAILURE;
D O I：
10.1001/jamaoncol.2018.1767
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1120 / 1121
页数：2
相关论文
共 50 条
  • [1] Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma
    Gordon, Leo I.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (5.5): : 716 - 718
  • [2] Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma
    Choi, Yun
    Diefenbach, Catherine S.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (01)
  • [3] Treatment of relapsed and refractory Hodgkin Lymphoma
    von Tresckow, Bastian
    Moskowitz, Craig H.
    SEMINARS IN HEMATOLOGY, 2016, 53 (03) : 180 - 185
  • [4] Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?
    Cencini, Emanuele
    Bocchia, Monica
    Fabbri, Alberto
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2021, 11 (03): : 261 - 265
  • [5] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
    Bekoz, Huseyin
    Ozbalak, Murat
    Karadurmus, Nuri
    Paydas, Semra
    Turker, Alev
    Toptas, Tayfur
    Tuglular, Tulin Firatli
    Altuntas, Fevzi
    Cakar, Merih Kizil
    Sonmez, Mehmet
    Gulbas, Zafer
    Demir, Nazli
    Kaynar, Leylagul
    Yildirim, Rahsan
    Karadogan, Ihsan
    Arat, Mutlu
    Kapucu, Irem
    Aslan, Nevin Alayvaz
    Ozkocaman, Vildan
    Turgut, Mehmet
    Yuksel, Meltem Kurt
    Ozcan, Muhit
    Hacioglu, Sibel Kabukcu
    Barista, Ibrahim
    Demirkaya, Metin
    Saydam, Guray
    Toprak, Selami K.
    Yilmaz, Mehmet
    Demirkol, Onur
    Ferhanoglu, Burhan
    ANNALS OF HEMATOLOGY, 2020, 99 (11) : 2565 - 2576
  • [6] Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
    Voorhees, Timothy J.
    Beaven, Anne W.
    CANCERS, 2020, 12 (10) : 1 - 16
  • [7] Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
    Tarekegn, Kidist
    Ramos, Ana Colon
    Singh, Balraj
    Gross, Harry G. Sequeira
    Gupta, Sachin
    WORLD JOURNAL OF ONCOLOGY, 2021, 12 (04) : 81 - 84
  • [8] Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents
    Spinner, Michael A.
    Sica, R. A.
    Tamaresis, John S.
    Lu, Ying
    Chang, Cheryl
    Lowsky, Robert
    Frank, Matthew J.
    Johnston, Laura J.
    Miklos, David B.
    Ly, Lori S. Muff
    Negrin, Robert S.
    Rezvani, Andrew R.
    Shiraz, Parveen
    Shizuru, Judith A.
    Weng, Wen -Kai
    Binkley, Michael S.
    Hoppe, Richard T.
    Advani, Ranjana H.
    Arai, Sally
    BLOOD, 2023, 141 (22) : 2727 - 2737
  • [9] Addressing an Unmet Need in Relapsed or Refractory Hodgkin Lymphoma comment
    Sheikh, Semira
    Kuruvilla, John
    JCO ONCOLOGY PRACTICE, 2021, 17 (02) : 74 - +
  • [10] Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma
    Colunga-Pedraza, Perla R.
    Vaquera-Alfaro, Hector A.
    Guzman-Martinez, Zulia
    Aleman-Jimenez, Marion Carolina
    Vega-Mateos, Antonio
    Gomez-De Leon, Andres
    Villela, Luis Mario
    Gomez-Almaguer, David
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5607 - 5614
12345